Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 3 (March)

1. Delayed versus immediate surgical intervention and prostate cancer outcome.
   J Natl Cancer Inst, 98(5): 355-7. [Abstract] [Full-text]
2. The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer.
   J Urol, 175(4): 1517-22. [Abstract] [Full-text]
3. Management of radiotherapy induced rectourethral fistula.
   J Urol, 175(4): 1382-7; discussion 1387-8. [Abstract] [Full-text]
4. Risk factors for the development of prostate brachytherapy related urethral strictures.
   J Urol, 175(4): 1376-80; discussion 1381. [Abstract] [Full-text]
5. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
   J Urol, 175(4): 1353-8. [Abstract] [Full-text]
6. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
   J Urol, 175(4): 1347-52. [Abstract] [Full-text]
7. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer.
   J Urol, 175(4): 1341-5; discussion 1345-6. [Abstract] [Full-text]
8. How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden.
   J Urol, 175(4): 1337-40. [Abstract] [Full-text]
9. Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population.
   J Urol, 175(4): 1332-6. [Abstract] [Full-text]
10. Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE.
    J Urol, 175(4): 1326-31. [Abstract] [Full-text]
11. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer.
    J Urol, 175(4): 1320-4; discussion 1324-5. [Abstract] [Full-text]
12. Real-time transrectal ultrasound guidance during nerve sparing laparoscopic radical prostatectomy: pictorial essay.
    J Urol, 175(4): 1311-9. [Abstract] [Full-text]
13. Real-time transrectal ultrasound guidance during laparoscopic radical prostatectomy: impact on surgical margins.
    J Urol, 175(4): 1304-10. [Abstract] [Full-text]
14. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer.
    J Urol, 175(4): 1298-302; discussion 1302-3. [Abstract] [Full-text]
15. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
    J Urol, 175(4): 1291-7. [Abstract] [Full-text]
16. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    J Urol, 175(4): 1286-90; discussion 1290. [Abstract] [Full-text]
17. Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population.
    J Urol, 175(4): 1281-5. [Abstract] [Full-text]
18. New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics.
    J Urol, 175(4): 1275-80. [Abstract] [Full-text]
19. Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis.
    Int J Cancer, 118(10): 2441-7. [Abstract] [Full-text]
20. Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.
    Int J Cancer, 118(10): 2538-42. [Abstract] [Full-text]
21. Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor.
    Int J Cancer, 118(10): 2485-9. [Abstract] [Full-text]
22. Association of body mass index and height with risk of prostate cancer among middle-aged Japanese men.
    Br J Cancer, 94(5): 740-2. [Abstract] [Full-text]
23. Leptomeningeal carcinomatosis in a patient with metastatic prostate cancer: case report and literature review.
    Surg Neurol, 65(4): 372-5, discussion 375-6. [Abstract] [Full-text]
24. Preparation and tumor affinity testing of the radioiodinated tetrahydroisoquinoline derivative [123I]TIC(OH) for targeting prostate cancer.
    Appl Radiat Isot, 64(5): 563-9. [Abstract] [Full-text]
25. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion.
    J Pathol, 208(5): 699-707. [Abstract] [Full-text]
26. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation.
    Biochem Biophys Res Commun, 342(4): 1284-90. [Abstract] [Full-text]
27. Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines.
    Biochem Biophys Res Commun, 342(4): 1263-72. [Abstract] [Full-text]
28. Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.
    BJU Int, 97(4): 691-7. [Abstract] [Full-text]
29. Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol.
    Life Sci, 78(18): 2099-104. [Abstract] [Full-text]
30. Hormone refractory prostate cancer: Management and advances.
    Cancer Treat Rev, 32(2): 90-100. [Abstract] [Full-text]
31. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers.
    Int J Cancer, 118(11): 2744-9. [Abstract] [Full-text]
32. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.
    Int J Cancer, 118(11): 2721-6. [Abstract] [Full-text]
33. Calcitonin stimulates the secretion of urokinase-type plasminogen activator from prostate cancer cells: its possible implications on tumor cell invasion.
    Int J Cancer, 118(11): 2694-702. [Abstract] [Full-text]
34. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic nude mice by green and black teas.
    Carcinogenesis, 27(4): 833-9. [Abstract] [Full-text]
35. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.
    Carcinogenesis, 27(4): 811-9. [Abstract] [Full-text]
36. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma.
    Hum Pathol, 37(4): 401-9. [Abstract] [Full-text]
37. Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model.
    Future Oncol, 2(2): 233-45. [Abstract] [Full-text]
38. Links between Propionibacterium acnes and prostate cancer.
    Future Oncol, 2(2): 225-32. [Abstract] [Full-text]
39. Phytanic acid, AMACR and prostate cancer risk.
    Future Oncol, 2(2): 213-23. [Abstract] [Full-text]
40. Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells.
    Biochem Biophys Res Commun, 343(1): 183-9. [Abstract] [Full-text]
41. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
    Cancer, 106(7): 1507-13. [Abstract] [Full-text]
42. Lymphovascular invasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomy.
    Cancer, 106(7): 1521-6. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.